ClinicalTrials.gg
CompletedNCT00731679TARGET 1Updated Nov 29, 2019Results posted

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

A Phase 3 interventional study of Rifaximin and Placebo in Non-Constipation Irritable Bowel Syndrome, sponsored by Bausch Health Americas, Inc.. Completed at 96 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-29.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
623
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 158 studies in Abdominal Pain with a site in United States — 23 open to participants now, 24 under way, 1 of them phase 3. Abdominal Pain · United States.

Enrollment
8th of 133
623 · median 61
Started
2008
with 8 others
Phase 3
11 of 158
1 open now
Registered
25th of 158
by date
Lead sponsor
4 of 158
Bausch Health Americas, Inc.

Among the 158 studies in Abdominal Pain with a site in United States, this one is the 8th largest by enrollment of the 133 interventional ones that give a count, is one of 9 that started in 2008, is one of 11 in phase 3, and was the 25th registered.

Abdominal Pain

388 studies on the registry are indexed under Abdominal Pain; 58 are open to participants now.

Browse Abdominal Pain studies →

Open to participants now

23 of the 158 studies in Abdominal Pain with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Abdominal Pain studies recruiting now, 13 (39%) set no upper age limit and 17 (52%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Abdominal Pain with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.

03

Conditions studied

  • Non-Constipation Irritable Bowel Syndrome

Keywords

  • IBS
  • Abdominal pain
  • Bloating
  • Diarrhea
  • Rifaximin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed IBS diagnosis per Rome II for diagnosis of IBS.
  • Colonoscopy within 2 years as part of IBS diagnostic evaluation.
  • Has active symptoms of non-constipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency.

Exclusion criteria

Exclusion Criteria:

  • Symptoms of constipation.
  • History of other gastrointestinal diseases.
  • Type 1 or 2 diabetes.
  • Lactose intolerance not controlled by lactose-free diet.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
623 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.

    Drug: Placebo

  • Experimental
    Rifaximin

    Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.

    Drug: Rifaximin

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).

    The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? \[Yes/No\]"

    Time frame: 4 weeks

Secondary outcomes

  1. Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).

    The secondary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of bloating was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? \[Yes/No\]."

    Time frame: 4 weeks

07

Results

Posted Jul 28, 2014

Participant flow

Participant flow — Overall Study
MilestonePlaceboRifaximin
Started314309
Completed292283
Not completed2226
Withdrew: Adverse event78
Withdrew: Withdrawal by subject88
Withdrew: Lost to follow-up78
Withdrew: Noncompliance01
Withdrew: Pregnancy01

Outcome measures

PrimaryProportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).

The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? \[Yes/No\]"

Time frame:
4 weeks
Reported as:
Number · percentage of responders
Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
percentage of respondersPlaceboRifaximin
Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).31.240.8
Statistical analysis
  • Placebo vs Rifaximin · Regression, Logistic · p = 0.01The p-value was obtained from a logistic regression model with fixed effects for treatment arm and analysis center.
SecondaryProportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).

The secondary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of bloating was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? \[Yes/No\]."

Time frame:
4 weeks
Reported as:
Number · percentage of responders
Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
percentage of respondersPlaceboRifaximin
Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).28.739.5
Statistical analysis
  • Placebo vs Rifaximin · Regression, Logistic · p = 0.005The p-value was obtained from a logistic regression model with fixed effects for treatment arm and analysis center.

Adverse events

Collected over 12 weeks. Adverse events were collected during the 2-week treatment period and during the 10-week follow-up period.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—8/314 (2.5%)101/314 (32.2%)
Rifaximin—3/309 (1%)103/309 (33.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPlaceboRifaximin
Road traffic accidentInjury, poisoning and procedural complications0/3141/309
CostochondritisMusculoskeletal and connective tissue disorders0/3141/309
Alcohol withdrawal syndromePsychiatric disorders0/3141/309
Rectal haemorrhageGastrointestinal disorders1/3140/309
Small intestinal obstructionGastrointestinal disorders1/3140/309
CholecystitisHepatobiliary disorders1/3140/309
Cholecystitis acuteHepatobiliary disorders1/3140/309
GastroenteritisInfections and infestations1/3140/309
Fracture nonunionMusculoskeletal and connective tissue disorders1/3140/309
AmnesiaNervous system disorders1/3140/309
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboRifaximin
Abdominal painGastrointestinal disorders23/31419/309
NauseaGastrointestinal disorders13/31422/309
HeadacheNervous system disorders16/31418/309
NasopharyngitisInfections and infestations18/3147/309
DiarrhoeaGastrointestinal disorders15/31414/309
SinusitisInfections and infestations12/3147/309
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders12/3148/309
VomitingGastrointestinal disorders8/31411/309
FlatulenceGastrointestinal disorders11/3146/309
CoughRespiratory, thoracic and mediastinal disorders4/3149/309

Baseline characteristics

The analysis population was the intent-to-treat population, defined as subjects who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)PlaceboRifaximinTotal
<=18 years112
Between 18 and 65 years275274549
>=65 years383472
Age, Continuous
Age, Continuous(years)PlaceboRifaximinTotal
Mean45.5 ± 14.646.2 ± 15.045.8 ± 14.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRifaximinTotal
Female222235457
Male9274166
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRifaximinTotal
American Indian or Alaska Native022
Asian123
Native Hawaiian or Other Pacific Islander101
Black or African American302454
White280281561
More than one race202
Unknown or Not Reported000
08

Study locations

96 sites
  • Hueytown, Alabama 35023, United States
  • Phoenix, Arizona 85050, United States
  • Sierra Vista, Arizona 85635, United States
  • Tucson, Arizona 85741, United States
  • Little Rock, Arkansas 72204, United States
  • Little Rock, Arkansas 72205, United States
  • Sherwood, Arkansas 72120, United States
  • Anaheim, California 92801, United States
  • Lancaster, California 93534, United States
  • Los Angeles, California 90045, United States
  • Murrieta, California 92562, United States
  • San Diego, California 92108, United States
  • Lakewood, Colorado 80215, United States
  • Bridgeport, Connecticut 06606, United States
  • Torrington, Connecticut 06790, United States
  • Altamonte Springs, Florida 32701, United States
  • Boynton Beach, Florida 33426, United States
  • Gainesville, Florida 32607, United States
  • Hollywood, Florida 33021, United States
  • Jupiter, Florida 33458, United States
  • Lauderdale Lakes, Florida 33319, United States
  • Maitland, Florida 32751, United States
  • Naples, Florida 34102, United States
  • New Port Richey, Florida 34652, United States
  • Orlando, Florida 32806, United States
  • West Palm Beach, Florida 33409, United States
  • Winter Garden, Florida 34787, United States
  • Winter Park, Florida 32708, United States
  • Topeka, Kansas 66606, United States
  • Shreveport, Louisiana 71103, United States
  • Baltimore, Maryland 21215, United States
  • Hagerstown, Maryland 21742, United States
  • Silver Spring, Maryland 20901, United States
  • Boston, Massachusetts 02115, United States
  • Detroit, Michigan 48235, United States
  • Kalamazoo, Michigan 49008, United States
  • Paw Paw, Michigan 49079, United States
  • Jackson, Mississippi 39202, United States
  • Saint Louis, Missouri 63141, United States
  • Lebanon, New Hampshire 03756, United States
  • Elizabeth, New Jersey 07202, United States
  • Lumberton, New Jersey 08048, United States
  • Bayside, New York 11358, United States
  • Brooklyn, New York 11214, United States
  • New York, New York 10021, United States
  • Troy, New York 12180, United States
  • Asheboro, North Carolina 27203, United States
  • Charlotte, North Carolina 28207, United States
  • Durham, North Carolina 27713, United States
  • Fayetteville, North Carolina 28304, United States
  • Greensboro, North Carolina 27408, United States
  • High Point, North Carolina 27262, United States
  • Mooresville, North Carolina 28117, United States
  • Raleigh, North Carolina 27609, United States
  • Salisbury, North Carolina 28144, United States
  • Wilmington, North Carolina 28401, United States
  • Fargo, North Dakota 58103, United States
  • Cincinnati, Ohio 45219, United States
  • Cleveland, Ohio 44122, United States
  • Columbus, Ohio 43215, United States
  • Dayton, Ohio 45440, United States
  • Zanesville, Ohio 43701, United States
  • Tulsa, Oklahoma 74104, United States
  • Portland, Oregon 97210, United States
  • Portland, Oregon 97225, United States
  • Lancaster, Pennsylvania 17601, United States
  • Germantown, Tennessee 38138, United States
  • Jackson, Tennessee 38301, United States
  • Johnson City, Tennessee 37604, United States
  • Nashville, Tennessee 37203, United States
  • Austin, Texas 78705, United States
  • Fort Worth, Texas 76104, United States
  • Houston, Texas 77074, United States
  • Houston, Texas 77090, United States
  • Pasadena, Texas 77504, United States
  • San Antonio, Texas 78215, United States
  • San Antonio, Texas 78229, United States
  • San Antonio, Texas 78258, United States
  • Tyler, Texas 75701, United States
  • Ogden, Utah 84405, United States
  • West Jordan, Utah 84088, United States
  • Chesapeake, Virginia 23320, United States
  • Lynchburg, Virginia 24502, United States
  • Bellevue, Washington 98004, United States
  • Spokane, Washington 99216, United States
  • West Bend, Wisconsin 53095, United States
  • St. John's, Newfoundland and Labrador A1E 2E2, Canada
  • Corunna, Ontario N0N 1G0, Canada
  • Hamilton, Ontario L8M 1K7, Canada
  • Hamilton, Ontario L8N 3Z5, Canada
  • Hamilton, Ontario L9N 4A6, Canada
  • London, Ontario N6A 5R8, Canada
  • London, Ontario N6A 5R9, Canada
  • Newmarket, Ontario L3Y 5G8, Canada
  • Niagara Falls, Ontario L2G 1J4, Canada
  • Sarnia, Ontario N7T 4X3, Canada
09

References and documents

Publications

  • Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409. PubMed 21208106 ↗
  • Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014 May;39(10):1161-8. doi: 10.1111/apt.12735. Epub 2014 Apr 3. PubMed 24697851 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2008
First posted
Aug 11, 2008
Start
Jul 2008
Primary completionActual
Aug 2009
CompletionActual
Sep 2009
Results first posted
Jul 28, 2014
Last update
Nov 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00731679
Responsible party
Sponsor
First posted
Aug 11, 2008
Start date
Jul 2008
Primary completion
Aug 2009
Completion
Sep 2009
Results posted
Jul 28, 2014
Last update
Nov 29, 2019

Study contacts

Enoch Bortey
study director · Bausch Health Americas, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion